GlaxoSmithKline announced that the Food and Drug Administration approved its supplemental new drug application for Promacta (eltrombopag), a once-daily medication for patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.
ViiV Healthcare announced that the Food and Drug Administration has approved Triumeq (abacavir 600 mg, dolutegravir 50 mg and lamivudine 300 mg) tablets for the treatment of HIV-1 infection.
With the National Association of Chain Drug Stores Total Store Expo currently underway in Boston, the Boston Globe published an op-ed in its opinion section, Podium, which was co-authored by Steven Anderson, president and CEO of NACDS and Michael Malloy, PharmD and dean of the MCPHS University School of Pharmacy - Worcester/Manchester.
“A drug store is not just for sick individuals. It’s the place to come to showcase wellness and promote health.”
The FBI has warned healthcare companies that hackers are targeting them and patient records, according to a flash alert the agency sent out earlier this week.
The Drug Enforcement Administration issued a final rule rescheduling hydrocodone combination products from schedule III to schedule II of the Controlled Substances Act.
The Food and Drug Administration cleared South Korean company Philosys’ Gmate blood-sugar monitoring device for U.S. marketing on Aug. 15.
The Centers for Disease Control and Prevention has announced recommendations of the Advisory Committee on Immunization Practices for the 2014-15 influenza season.
GlaxoSmithKline announced FDA approval for Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid medicine for the treatment of asthma in patients 12 years of age and older.
Restricting access to samples of generic biological drugs would lead to nearly $140 million in lost savings for every $1 billion in biologics sales, Matrix Global Advisors said.